Scientific deep-dive
Do GLP-1 Drugs Reduce Dementia Risk? Three Analyses, Three Answers
In 10 GLP-1 trials, dementia odds were 45% lower, but pooled across all 23 trials reporting dementia the result was not significant. A cohort study found 33% lower risk; a BMJ living review found nothing significant, at low certainty.
Three respectable analyses published in 2025 looked at whether these drugs reduce dementia risk, and they do not agree. In a meta-analysis of 26 randomized trials, the 10 that tested GLP-1 drugs showed 45% lower odds of dementia, although the pooled result across the 23 trials that reported dementia was not significant.[1] A cohort study drawn from 396,963 patients with type 2 diabetes found a 33% lower risk.[2] A continuously updated network meta-analysis in the BMJ found no significant effect at all, and graded its own certainty as low.[3] Anyone who has read one headline about this has read a third of the evidence.
Why anyone thinks there might be an effect
Diabetes is an established risk factor for dementia, and the mechanisms proposed to link them (vascular damage, insulin signaling in the brain, chronic inflammation) are all things a glucose-lowering drug might plausibly touch. GLP-1 receptors also exist in the brain, which is why these drugs affect appetite at all, so a direct neurological effect is not far-fetched. The same idea has been raised for epilepsy, where a records study found fewer new cases on GLP-1 drugs, though a pattern inside its numbers points away from neuroprotection.
Plausible mechanism plus observational signal is the combination that has repeatedly failed in dementia research. Hormone replacement therapy, vitamin E and NSAIDs all looked protective in cohort studies and did not survive randomized testing. That history is the reason to read what follows carefully rather than hopefully.
What each analysis found
| Study | Design | Result |
|---|---|---|
| JAMA Neurology[1] | Meta-analysis of 26 randomized trials, 164,531 participants | GLP-1RAs (10 of the 26 trials): OR 0.55 (0.35–0.86) |
| JAMA Neurology[2] | Target trial emulation, 396,963 screened, 33,858 in the GLP-1 comparison | HR 0.67 (0.47–0.96); 2.26 fewer cases per 1,000 person-years |
| BMJ[3] | Living systematic review and network meta-analysis | OR 0.92 (0.83–1.02) — not significant, low certainty |
The first two are the ones that made the news. The third is the one that keeps being updated, and its authors describe the question as uncertain in as many words.[3]
The disagreement inside the positive results
One detail usually gets lost, and it says more than any single number. The meta-analysis of trials found GLP-1 drugs significantly protective and SGLT2 inhibitors not (OR 1.20, 0.67–2.17), with a formal test confirming the two classes behaved differently.[1] The cohort study found both classes protective, and no difference between them at all (HR 0.97).[2]
If this were a straightforward property of the drug, those two results would agree.
That they do not points at something else. Possibly what is being measured is better diabetes care rather than a specific molecule; possibly dementia diagnoses in health records depend on who is being seen and how often. Both studies are good. The tension between them is a finding in itself.
What would settle it
A trial designed for the question, powered for it, and long enough to matter. Those are being run, and they will report years from now. How the dementia signal fits with the death, cancer and muscle data is in our longevity evidence review.
Until then, the BMJ’s verdict stands: uncertain. That is not a satisfying answer, but it is the accurate one, and it is the one to hold against the marketing that has already begun. If someone is selling you a GLP-1 on a dementia claim, they are ahead of three analyses that cannot agree with each other.
For what these drugs demonstrably do across other systems, our beyond-the-scale article sorts the established effects from the associations, and the substance use piece works through a similar pattern of large cohort signals meeting disappointing trials.
Frequently Asked Questions
References
- 1.Seminer A, Mulihano A, O'Brien C, et al. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis JAMA Neurology. 2025. PMID: 40193122.
- 2.Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias JAMA Neurology. 2025. PMID: 40193118.
- 3.Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis BMJ. 2025. PMID: 40813122.
Compare the sellers
Related research
GLP-1 Drugs and Hidradenitis Suppurativa: Early Studies, No Trial
Early studies of liraglutide and semaglutide report improvement in HS severity and quality of life. There is no randomized trial, and weight loss by other means has had mixed results in this condition, which complicates the obvious explanation.
5 min read
DSIP: A Sleep Peptide Named in 1977, With No Known Receptor
Delta sleep-inducing peptide was isolated in 1977 and named after a brain-wave effect seen in rabbits. A review of the field states the sleep hypothesis is extremely poorly documented and weak, and that no gene, protein or receptor has been isolated.
4 min read
What We Can and Cannot Verify
Five errors found in our own live pages in one week, all named. Plus the standing limits: 182 unverified LegitScript claims, 324 sellers with no state list, and the things nobody can check from outside.
6 min read
PT-141 (Bremelanotide): What the Evidence Shows
PT-141 is bremelanotide, approved as Vyleesi only for low sexual desire in premenopausal women. Its phase 3 trials found small gains in desire and no rise in satisfying sexual events. The men's program stopped in 2007 over blood pressure.
11 min read
KPV: What the Evidence Shows, and What FDA Found
KPV, a fragment of alpha-MSH, calmed gut inflammation in mouse colitis studies. FDA's 2026 review found no human data. It is not approved or on the 503A bulks list; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against topical or oral 503A compounding under strict conditions.
9 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The most detailed published evidence that GLP-1 drugs cause dry mouth is three case reports, alongside an adverse-event reporting signal for semaglutide. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →